USV Pharma is in advanced talks to acquire an 85% stake in Wellbeing Nutrition at a Rs 1,600 crore valuation, marking a major move into India’s fast-growing consumer health and supplements market.
.jpeg "Aurobindo Pharma's Biosimilar Growth to Peak by 2029, CEO Says")
Aurobindo Pharma aims for significant biosimilar growth by 2029, with approved oncology products and strategic plans for Europe and Latin America markets, says CEO Satakarni Makkapati.
Kashiv BioSciences has signed an exclusive licensing and supply agreement with Intas Pharmaceuticals to commercialize a complex peptide product across Europe, the UK, and India, expanding its global footprint.
Sanofi has received FDA breakthrough therapy designation for Wayrilz to treat warm autoimmune hemolytic anemia, a rare disorder with no approved targeted therapies. Japan has also granted orphan status.
Natco Pharma has received High Court approval to manufacture and export semaglutide, strengthening its entry into the global diabetes and obesity drug market and expanding its presence in metabolic disorder treatments.
The merger of Auro Vaccines and Curateq Biologics, a part of Aurobindo Pharma, was approved today during a board meeting of the company held.
.jpeg "MedGenome Launches MetaSeq to Identify 1,400+ Pathogens in One Test")
MedGenome launches MetaSeq, an advanced blood test using NGS to detect 1,400+ pathogens in just five days, offering faster, more accurate diagnosis for bloodstream infections.
.png "AstraZeneca Pharma India Gets CDSCO Approval for Imfinzi")
AstraZeneca Pharma India has received CDSCO approval to import and market Imfinzi for an additional cancer indication, expanding treatment options for advanced and recurrent endometrial cancer patients in India.
.png "Eli Lilly Acquires Orna to Advance In Vivo CAR-T Therapies")
Eli Lilly has agreed to acquire Orna Therapeutics in a deal valued at up to $2.4 billion, strengthening its position in in vivo CAR-T therapies and expanding options for patients with B cell-driven autoimmune diseases.
Takeda Pharmaceutical has signed a major $1.7 billion deal with biotech firm Iambic, marking a fresh push to use AI drug discovery to speed up small-molecule research in cancer and gastrointestinal diseases.
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")